The Multinational Impact of Migraine Symptoms on Healthcare Utilisation and Work Loss

Gerth, William C.; Carides, George W.; Dasbach, Erik J.; Visser, W. Hester; Santanello, Nancy C.

doi:10.2165/00019053-200119020-00006

Cited by 86 publications

(59 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, as migraine and tension-type headache are comorbid, estimates of migraine alone or tension-type headache alone may inadvertently capture lost productive time due to the other disorder. C o n s i s t e n t w i t h o t h e r s t u dies, 5,6,9,26,27,[30][31][32][33][34] reduced performance while at work was the dominant source (ie, 80% of the lost productive time and 76.6% of the lost productive timerelated cost) of pain-related lost productive time in the US workforce. In previous studies of headache disorders, including daily diary studies of migraine, health-related reduced performance on days at work is a more significant cause of lost work time than absenteeism.…”

Section: -59mentioning

confidence: 99%

Lost Productive Time and Cost Due to Common Pain Conditions in the US Workforce

Stewart

Ricci

Chee

et al. 2003

JAMA

1,359

894

View full text Add to dashboard Cite

Context Common pain conditions appear to have an adverse effect on work, but no comprehensive estimates exist on the amount of productive time lost in the US workforce due to pain.Objective To measure lost productive time (absence and reduced performance due to common pain conditions) during a 2-week period. Design and SettingCross-sectional study using survey data from the American Productivity Audit (a telephone survey that uses the Work and Health Interview) of working adults between August 1, 2001, and July 30, 2002. Participants Random sample of 28902 working adults in the United States. Main Outcome Measures Lost productive time due to common pain conditions (arthritis, back, headache, and other musculoskeletal) expressed in hours per worker per week and calculated in US dollars.Results Thirteen percent of the total workforce experienced a loss in productive time during a 2-week period due to a common pain condition. Headache was the most common (5.4%) pain condition resulting in lost productive time. It was followed by back pain (3.2%), arthritis pain (2.0%), and other musculoskeletal pain (2.0%). Workers who experienced lost productive time from a pain condition lost a mean (SE) of 4.6 (0.09) h/wk. Workers who had a headache had a mean (SE) loss in productive time of 3.5 (0.1) h/wk. Workers who reported arthritis or back pain had mean (SE) lost productive times of 5.2 (0.25) h/wk. Other common pain conditions resulted in a mean (SE) loss in productive time of 5.5 (0.22) h/wk. Lost productive time from common pain conditions among active workers costs an estimated $61.2 billion per year. The majority (76.6%) of the lost productive time was explained by reduced performance while at work and not work absence. ConclusionsPain is an inordinately common and disabling condition in the US workforce. Most of the pain-related lost productive time occurs while employees are at work and is in the form of reduced performance.

show abstract

Section: -59mentioning

confidence: 99%

Lost Productive Time and Cost Due to Common Pain Conditions in the US Workforce

Stewart

Ricci

Chee

et al. 2003

JAMA

1,359

894

View full text Add to dashboard Cite

show abstract

“…Migraine headaches are associated with high morbidity and significant loss of productivity [1,2]. Across all age groups, migraineurs are more likely to experience ischaemic stroke than non-migraineurs (relative risk [RR] 2.16, 95% confidence interval [CI] 1.89-2.48), especially migraineurs who have aura (RR 2.88, 95% CI 1.89-4.39) [3].…”

Section: Introductionmentioning

confidence: 99%

Migraineurs with patent foramen ovale have larger right-to-left shunt despite similar atrial septal characteristics

et al. 2007

View full text Add to dashboard Cite

The objective of the study was to assess differences in proportion of large right-to-left shunt (RLS) and atrial septal characteristics between migraineurs and non-migraineurs referred for transcatheter closure of patent foramen ovale (PF0). This retrospective study took place in a large metropolitan medical centre. The patients were migraineurs with aura (n=52), migraineurs without aura (n=19) and non-migraineurs (n=149). RLS was evaluated before closure using bilateral power m-mode transcranial Doppler at rest and after calibrated, sustained Valsalva manoeuvre, and graded with a validated 0-5 scale. Intracardiac echocardiography was used to assess atrial septal characteristics. Migraineurs had a higher proportion of large RLS (Grade IV or V) than nonmigraineurs at rest and after calibrated Valsalva (rest, p=0.04; Valsalva, p=0.01). Atrial septal characteristics were similar between groups. Migraine is associated with larger RLS at rest and strain; however migraine status does not predict PFO characteristics.

show abstract

“…1 Migraine symptoms result in a considerable burden with regard to health care utilization, health care costs, and work/productivity loss due to disability and decreased functional status. [2][3][4][5][6] Clinical trials have demonstrated that sumatriptan (Imitrex®, GlaxoSmithKline) is effective in relieving migraine pain. These studies have established the efficacy of sumatriptan among patients who treated their migraines at a point in which their headache pain was classified as moderate or severe.…”

mentioning

confidence: 99%

Pain Free Efficacy of Sumatriptan in the Early Treatment of Migraine

Jelinski

Becker²,

Christie³

et al. 2006

Can J Neurol Sci.

View full text Add to dashboard Cite

Migraine is a common neurological disorder that is characterized by episodic headaches associated with symptoms such as nausea, visual disturbances, photophobia, and phonophobia. In Canada, approximately 7% of adult males and 22% of adult females suffer from migraine. 1 Migraine symptoms result in a considerable burden with regard to health care utilization, health care costs, and work/productivity loss due to disability and decreased functional status. [2][3][4][5][6] Clinical trials have demonstrated that sumatriptan (Imitrex®, GlaxoSmithKline) is effective in relieving migraine pain. These studies have established the efficacy of sumatriptan among patients who treated their migraines at a point in which their headache pain was classified as moderate or severe. 7-11 However, ABSTRACT: Background: There is evidence that headache response rates may be higher if triptans are used early when a migraine attack is still mild, as compared to when it is treated after pain has reached moderate or severe intensity. Methods: In this randomized, double blind, placebo controlled, parallel group clinical trial, 361 patients took either placebo, sumatriptan 50 mg, or sumatriptan 100 mg in a single attack study. The primary outcome measure was pain-free status at two hours. Results: In the intention to treat group, two hour pain free rates were 16%, 40%, and 50% in the placebo group, sumatriptan 50 mg group, and the sumatriptan 100 mg group respectively (p<0.001, active treatment groups vs. placebo). Conclusions: Both sumatriptan 50 mg and 100 mg were significantly superior to placebo for the pain-free end point at two hours. The pain-free response rates in this trial where sumatriptan was taken while the headache was still mild were generally higher than in older clinical trials where headache was treated after reaching a moderate or severe intensity. RÉSUMÉ: Absence de douleur comme mesure de l'efficacité du sumatriptan pour le traitement précoce de la migraine. Contexte: Le taux de réponse serait plus élevé si les triptans sont utilisés tôt au cours d'une crise de migraine alors que les symptômes sont légers plutôt que quand la douleur est devenue modérée ou sévère. Méthodes: Il s'agit d'une étude de pharmacologie clinique randomisée, à double insu, avec placebo et groupes parallèles. 361 patients ont pris soit le placebo, le sumatriptan 50 mg ou le sumatriptan 100 mg au cours d'une seule crise migraineuse. Le critère d'évaluation primaire était l'absence de douleur 2 heures après la prise du médicament. Résultats: À l'analyse selon l'intention de traitement, le taux de patients sans douleur était de 16%, 40% et 50% pour le groupe placebo, le groupe sumatriptan 50 mg et le groupe sumatriptan 100 mg respectivement (groupes traitement actif versus placebo, p > 0,001). Conclusions: Le sumatriptan 50 mg et 100 mg étaient significativement supérieurs au placebo quant au critère d'évaluation primaire, soit l'absence de douleur 2 heures après la prise du médicament. Le taux de réponse, soit l'absence de douleur, dans cette étude ...

show abstract

The Multinational Impact of Migraine Symptoms on Healthcare Utilisation and Work Loss

Cited by 86 publications

References 7 publications

Lost Productive Time and Cost Due to Common Pain Conditions in the US Workforce

Lost Productive Time and Cost Due to Common Pain Conditions in the US Workforce

Migraineurs with patent foramen ovale have larger right-to-left shunt despite similar atrial septal characteristics

Pain Free Efficacy of Sumatriptan in the Early Treatment of Migraine

Contact Info

Product

Resources

About